Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Daptomycin In Sodium Chloride
Brand Name
Daptomycin In Sodium Chloride
Generic Name
Daptomycin In Sodium Chloride
Active Ingredient
DaptomycinCategory
Lipopeptide Antibacterial [EPC]
Variants
4
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Daptomycin In Sodium Chloride, you must consult a qualified healthcare professional.
| 700 mg/100mL | INJECTION, SOLUTION | INTRAVENOUS | 0338-0716 |
Detailed information about Daptomycin In Sodium Chloride
Daptomycin is a potent cyclic lipopeptide antibacterial indicated for the treatment of complicated skin infections and Staphylococcus aureus bloodstream infections, including MRSA. It works by disrupting bacterial cell membrane function.
Dosage for daptomycin is strictly weight-based, meaning the amount of medicine you receive depends on your body weight (measured in kilograms). Healthcare providers typically use the patient's total body weight to calculate the dose. Standard adult dosing regimens include:
In some clinical settings, higher doses (e.g., 8 mg/kg to 10 mg/kg) may be used off-label for highly resistant infections or complex cases, but this increases the risk of side effects and must be closely monitored by a specialist.
Daptomycin is FDA-approved for use in pediatric patients aged 1 year and older. The dosing for children is also weight-based but varies significantly by age due to differences in how children clear the drug:
Daptomycin is not currently approved for infants under the age of 1 year.
Because daptomycin is primarily excreted by the kidneys, patients with decreased kidney function require dosage adjustments to prevent the drug from accumulating to toxic levels. For patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, including those on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), the dosing frequency is typically changed from once every 24 hours to once every 48 hours. Your doctor will monitor your kidney function (serum creatinine) closely during treatment.
No dosage adjustment is generally required for patients with mild to moderate hepatic (liver) impairment (Child-Pugh Class B). However, daptomycin has not been extensively studied in patients with severe hepatic impairment (Child-Pugh Class C), so it should be used with caution in this population.
Dosage selection for elderly patients should be cautious, usually starting at the lower end of the dosing range. This is primarily because older adults are more likely to have decreased renal function. Healthcare providers will evaluate the patient's CrCl before and during treatment.
Daptomycin is administered only by intravenous (IV) route. It can be given in two ways:
Storage of the dry powder should be in a refrigerator (36°F to 46°F or 2°C to 8°C). Once the drug is reconstituted (mixed with liquid), it must be used within a specific timeframe (usually 12 hours at room temperature or 48 hours if refrigerated) to ensure potency and sterility.
In a hospital setting, missing a dose is unlikely as the medical staff manages the schedule. However, if you are receiving daptomycin through a home infusion service and miss a dose, contact your healthcare provider or infusion nurse immediately. Do not double the dose to catch up. Maintaining a consistent schedule is vital for ensuring the antibiotic stays at a therapeutic level in your blood to fight the infection effectively.
Symptoms of a daptomycin overdose are not well-documented but may include an intensification of side effects, particularly muscle pain or weakness. In the event of an overdose, supportive care is provided. While daptomycin can be removed by hemodialysis, only about 15% of the dose is removed over a 4-hour period, so dialysis is not an efficient primary method for treating an acute overdose. If an overdose is suspected, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this can lead to antibiotic resistance or treatment failure.
While daptomycin is generally well-tolerated, some patients may experience common side effects during their course of treatment. These are typically mild and often resolve once the medication is discontinued. Common side effects include:
Daptomycin is a powerful antibiotic that requires careful medical supervision. Before starting treatment, patients must inform their healthcare provider of their full medical history, especially any history of kidney disease, muscle disorders, or previous allergic reactions to antibiotics. Because daptomycin is administered intravenously, it is usually given in a hospital or specialized infusion center where patients can be monitored for immediate adverse reactions.
No FDA black box warnings for Daptomycin. While it lacks a black box warning, the FDA requires prominent warnings in the prescribing information regarding the risks of skeletal muscle effects (myopathy) and potential lung injury (eosinophilic pneumonia).
There are no drugs that are strictly contraindicated (never to be used) with daptomycin based on chemical incompatibility in the body; however, certain drugs should be avoided due to additive toxicity.
There are very few absolute contraindications for daptomycin, but they are critical to observe:
These are conditions where the drug should be used with extreme caution and only if the benefits outweigh the risks:
Daptomycin is classified as Pregnancy Category B (under the older FDA system). This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. According to the FDA, daptomycin should be used during pregnancy only if clearly needed. It is not known to be teratogenic (causing birth defects) in animal models, but human data is limited. Healthcare providers will perform a risk-benefit analysis, considering the severity of the mother's infection versus the potential unknown risks to the developing fetus.
Limited data indicate that daptomycin is excreted into human milk in very small amounts. The oral bioavailability of daptomycin is extremely low, meaning it is unlikely that a nursing infant would absorb significant amounts of the drug through breast milk. However, the potential for alterations in the infant's gut flora (the "good" bacteria in the digestive system) exists. Mothers should consult their healthcare provider about whether to continue breastfeeding or temporarily pump and discard milk during treatment.
Daptomycin is approved for children aged 1 to 17 years. It is specifically indicated for cSSSI and
Daptomycin is a cyclic lipopeptide that exhibits a unique, calcium-dependent mechanism of action. The molecule consists of a 13-amino acid peptide core with a decanoyl side chain. In the presence of physiological calcium levels, daptomycin undergoes a conformational change that allows it to bind to the bacterial cytoplasmic membrane. The lipophilic tail inserts into the phospholipid bilayer, specifically targeting areas rich in phosphatidylglycerol. This insertion causes the formation of transmembrane channels or pores, leading to a rapid efflux of intracellular potassium ions (K+). This loss of membrane potential (depolarization) results in the inhibition of DNA, RNA, and protein synthesis, leading to rapid cell death without lysing (bursting) the cell. This "non-lytic" killing may be beneficial in reducing the release of inflammatory bacterial toxins.
Daptomycin exhibits concentration-dependent bactericidal activity. This means that higher peak concentrations of the drug (Cmax) relative to the Minimum Inhibitory Concentration (MIC) of the bacteria result in faster and more complete killing. It also possesses a significant post-antibiotic effect (PAE), where bacterial growth continues to be suppressed even after the drug concentration falls below the MIC. There is no evidence of cross-resistance with other antibiotic classes, although rare cases of "daptomycin-nonsusceptible" strains have emerged during prolonged therapy, often involving mutations in the mprF or yycF genes.
Common questions about Daptomycin In Sodium Chloride
Daptomycin is a potent intravenous antibiotic used to treat serious infections caused by Gram-positive bacteria. Its primary FDA-approved uses include complicated skin and skin structure infections (cSSSI) and bloodstream infections (bacteremia) caused by *Staphylococcus aureus*, including MRSA. It is also used to treat right-sided infective endocarditis, which is an infection of the heart valves. Because of its strength, it is often reserved for cases where other antibiotics have failed or when the infection is particularly severe. It is important to note that daptomycin is not used for pneumonia because it is inactivated by substances in the lungs.
The most common side effects of daptomycin include gastrointestinal issues such as diarrhea, nausea, and vomiting. Some patients may also experience headaches, dizziness, or insomnia during their treatment course. Injection site reactions, such as redness or swelling where the IV was placed, are also frequently reported. While these are usually mild, healthcare providers monitor patients closely for more serious issues. If you experience unexplained muscle pain or shortness of breath, you should notify your medical team immediately, as these could be signs of more significant complications.
There is no known direct chemical interaction between daptomycin and alcohol. However, healthcare providers generally recommend avoiding alcohol while being treated for a serious bacterial infection. Alcohol can dehydrate the body, weaken the immune system, and put additional stress on the liver and kidneys, which are already working hard to process the medication and fight the infection. Staying hydrated and well-rested is crucial for the success of antibiotic therapy. Always check with your doctor to see if your specific health condition allows for moderate alcohol consumption.
Daptomycin is considered a Pregnancy Category B medication, meaning there is no evidence of harm in animal studies, but there are no comprehensive studies in pregnant humans. It should only be used during pregnancy if the potential benefit to the mother clearly outweighs the potential risk to the fetus. If you are pregnant or planning to become pregnant, your doctor will carefully evaluate the severity of your infection before prescribing this drug. Most healthcare providers will only use daptomycin in pregnancy for life-threatening infections like MRSA bacteremia where other safer alternatives are not effective.
Daptomycin begins working at the molecular level almost immediately after the intravenous dose is administered, rapidly killing susceptible bacteria. However, patients may not notice a significant improvement in their physical symptoms for 48 to 72 hours. The total duration of treatment depends on the type of infection; skin infections may require 7 to 14 days, while bloodstream infections or heart valve infections may require 2 to 6 weeks of therapy. It is essential to complete the entire course of treatment even if you start feeling better after the first few doses.
You should never stop taking daptomycin or any antibiotic suddenly without consulting your healthcare provider. Stopping the medication early can allow the remaining bacteria to multiply, potentially leading to a relapse of the infection. Furthermore, incomplete treatment is a major cause of antibiotic resistance, where bacteria evolve to become immune to the drug. If you are experiencing side effects that make you want to stop the medication, talk to your doctor immediately so they can determine if a different antibiotic is appropriate for your condition.
If you are receiving daptomycin in a hospital, the staff will manage your schedule to ensure no doses are missed. If you are receiving home infusion therapy and miss a dose, contact your infusion nurse or doctor right away. They will provide instructions on when to administer the next dose. Do not attempt to "double up" on doses to make up for a missed one, as this can increase the risk of muscle toxicity. Maintaining a consistent 24-hour (or 48-hour in renal patients) schedule is vital for the drug's effectiveness.
Weight gain is not a recognized or common side effect of daptomycin. Most patients receiving this medication are fighting serious infections, which more commonly causes weight loss due to decreased appetite or the metabolic demands of the illness. If you notice rapid weight gain or swelling (edema) in your legs or feet while taking daptomycin, you should report this to your doctor. Such swelling could be a sign of kidney issues or other underlying complications rather than a direct effect of the medication itself on body fat.
Daptomycin can interact with several other medications, most notably statins (cholesterol-lowering drugs like Lipitor or Zocor). Taking these together significantly increases the risk of muscle damage, so doctors usually pause statin therapy during daptomycin treatment. It can also interfere with blood-thinning tests (PT/INR) and interact with certain other antibiotics like aminoglycosides. Always provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking to ensure a safe treatment plan.
Yes, daptomycin is available as a generic medication. The original brand-name version, Cubicin, lost its patent protection several years ago, allowing other manufacturers to produce generic versions. Generic daptomycin is therapeutically equivalent to the brand-name drug, meaning it has the same active ingredient, strength, and dosage form. Using the generic version can significantly reduce the cost of treatment for patients and healthcare facilities while providing the same level of efficacy in treating serious Gram-positive bacterial infections.
Other drugs with the same active ingredient (Daptomycin)
> Warning: Stop taking Daptomycin and call your doctor immediately if you experience any of these serious symptoms. Prompt medical evaluation is necessary to prevent long-term complications.
Daptomycin is typically used for short-term acute infections (up to 6 weeks). Long-term use (months) is rare and significantly increases the risk of peripheral neuropathy and persistent elevations in creatine phosphokinase (CPK) levels. Prolonged use may also lead to the development of drug-resistant bacteria, making future infections harder to treat.
As of the current 2024-2026 FDA updates, Daptomycin does not carry a Black Box Warning. However, the warnings regarding myopathy and eosinophilic pneumonia are considered major clinical precautions that carry nearly the same weight in clinical decision-making. Healthcare providers are mandated to monitor CPK levels weekly to ensure patient safety.
Report any unusual symptoms, especially muscle pain or breathing difficulties, to your healthcare provider immediately.
To ensure safety, the following monitoring is typically required during daptomycin therapy:
Daptomycin is not known to significantly impair the ability to drive or operate machinery. However, since dizziness and headaches are possible side effects, patients should observe how they react to the medication before engaging in activities that require alertness.
There are no specific contraindications regarding alcohol use and daptomycin. However, alcohol can dehydrate the body and strain the liver and kidneys, which are already processing the infection and the medication. It is generally advised to avoid alcohol while fighting a serious infection to help the immune system recover.
It is critical to complete the full course of daptomycin as prescribed by your doctor. Stopping the medication too early, even if you feel better, can allow the remaining bacteria to continue growing and potentially develop resistance to the antibiotic. There is no "withdrawal syndrome" associated with daptomycin, but the risk of infection relapse is high if the course is incomplete.
> Important: Discuss all your medical conditions and current medications with your healthcare provider before starting Daptomycin.
Because daptomycin is administered intravenously, there are no direct interactions with food, dairy, or caffeine. Absorption is not an issue since the drug bypasses the digestive tract entirely. However, maintaining adequate hydration is important to support kidney function during treatment.
As mentioned, daptomycin can interfere with prothrombin time (PT) and International Normalized Ratio (INR) assays. It can also cause false-positive results in some urinary protein screening tests. Always inform laboratory personnel if you are being treated with daptomycin.
For each major interaction, the management strategy involves either temporary discontinuation of the interacting agent (as with statins), increased frequency of laboratory monitoring (as with aminoglycosides), or careful timing of blood draws (as with warfarin).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.
There is no known cross-sensitivity between daptomycin and other major antibiotic classes like penicillins, sulfonamides, or macrolides. This makes daptomycin a valuable alternative for patients with severe allergies to other antibiotics. However, patients who have had reactions to other lipopeptides (though few exist in clinical use) should be treated with extreme caution.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies, before prescribing Daptomycin.
Clinical studies of daptomycin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function, dose adjustments are frequently necessary. The risk of myopathy may also be slightly higher in the elderly, especially those on multiple medications (polypharmacy). Monitoring of renal function and CPK levels is particularly important in this age group.
In patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, the elimination of daptomycin is significantly delayed. The FDA-approved adjustment is to extend the dosing interval to every 48 hours. For patients on hemodialysis, the dose should be administered after the dialysis session on dialysis days. Failure to adjust the dose in renal impairment significantly increases the risk of CPK elevation and myopathy.
For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), no adjustment is needed. The pharmacokinetics of daptomycin are not significantly altered by liver disease. However, for those with severe hepatic impairment (Child-Pugh Class C), data is lacking, and daptomycin should be used with caution and frequent clinical monitoring.
> Important: Special populations require individualized medical assessment to ensure the safest and most effective use of this potent antibiotic.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | 90% to 93% (primarily Albumin) |
| Half-life | 8 to 9 hours (Adults) |
| Tmax | End of 30-min infusion |
| Metabolism | Minimal (No CYP450 involvement) |
| Excretion | Renal (78%), Fecal (5%) |
| Volume of Distribution | 0.1 L/kg |
Daptomycin is the founding member of the cyclic lipopeptide antibacterial class. While other lipopeptides exist (such as polymyxins), daptomycin is unique in its specific activity against Gram-positive organisms and its calcium-dependent membrane depolarization mechanism. It is often grouped with "last-resort" Gram-positive agents like linezolid and tigecycline.